SNP-610

Phase 2Small molecule

SSinew Pharma Inc.

SNP-610 is one of 21 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic SteatohepatitisNot yet recruiting

Non-Alcoholic SteatohepatitisPhase 2

Not yet recruiting

Competition

Competitive Landscape

22 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

3 2

Estrace

Rifadin

Aldactone

Cytotec

Mounjaro

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Trental

VValidus Pharmaceuticals

Approved

1 9

Ozempic

Novo Nordisk

Phase 3

4 10

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Not yet recruiting

Non-Alcoholic Steatohepatitis

NCT03468556

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis

Not yet recruiting·SSinew Pharma Inc.·Phase 2·NCT03468556·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SNP-610. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SNP-610 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SNP-610. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sinew Pharma Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSinew Pharma Inc.

SNP-610

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News